Oncotarget is a peer-reviewed, open-access biomedical journal indexed in MEDLINE, PubMed, PMC, Scopus, and more.
Orchard Park, NY
Joined February 2016
- Tweets16.3K
- Following3.7K
- Followers3.4K
- Likes6.8K
Pinned Tweet
🔬 Scientific integrity is at the core of scholarly publishing.
A new editorial from Oncotarget highlights publishing industry trends, measurable journal comparisons, and future strategy.
🔗 doi.org/10.18632/oncotarget.…
#ScientificIntegrity #AcademicPublishing #OA #Research
ALT Figure 4: Post-tools era. Oncotarget versus Scientific Reports and PLOS One. The percentage of “High risk” articles identified by the tool “Argos” (as of 3/05/2026) in relation to the total number of articles published in a journal during a specific year in 2019–2025.
📈 #TrendingWithImpact:
“Case Report WIN-MTB-2024001 – WIN International Molecular Tumor Board: A 55-year-old male with glioblastoma exhibiting amplifications in MDM2 and EGFR” @BrownUniversity
🔗 bit.ly/4BifOUy
#Cancer #Quote #Glioblastoma #Oncotarget ##CaseReport
🎧 Listen to our #PressRelease on the #CaseReport "Case Report WIN-MTB-2024001 – WIN International Molecular Tumor Board: A 55-year-old male with glioblastoma exhibiting amplifications in MDM2 and EGFR."
soundcloud.com/oncotarget/in…
#Cancer #Podcast #Audio #SoundCloud #Glioblastoma
🎥 #OncotargetShort:
Abstract #Video about the #CaseReport "Case Report WIN-MTB-2024001 – WIN International Molecular Tumor Board: A 55-year-old male with glioblastoma exhibiting amplifications in MDM2 and EGFR." @BrownUniversity
🔗 bit.ly/4BifOUy
#Cancer #Glioblastoma
📈 #TrendingWithImpact:
"Case Report WIN-MTB-2024001 – WIN International Molecular Tumor Board: A 55-year-old male with glioblastoma exhibiting amplifications in MDM2 and EGFR"
#PressRelease ⬇️
bit.ly/4iboH9E
#Cancer #Glioblastoma #CaseReport #OA #Oncotarget #Press
🛡️ To maintain scientific integrity and reduce the risk of costly settlements related to image fraud, we recommend institutions subscribe to image forensics tools, establish dedicated image forensics teams, and encourage researchers to screen their manuscripts before publication.
ALT Oncotarget Scientific Integrity
#PaperoftheDay: "Small bowel GIST harboring concurrent KIT exon 9 duplication and SDHC mutation: A case report"
DOI ⬇️
doi.org/10.18632/oncotarget.…
#Cancer #Oncology #OpenAccess #Research #Publishing #PeerReviewed #Journal
✅ Could PD-1/PD-L1 inhibitors improve outcomes for patients with high-risk solid tumors?
A new meta-analysis examined the efficacy and safety of immune checkpoint inhibitors as adjuvant cancer therapies.
#Summary ⬇️
oncotarget.org/2026/05/20/im…
#cancer #immunotherapy #research #oa
🌐 Visit Oncotarget.org to read #blog synopses of new and #trending #research papers published by Oncotarget.
#openaccess #peerreviewed #oncology #cancer #researchpapers #science #medicine #medEd #OA
📘 #Editors, #authors & #reviewers:
Follow ethical best practices and ICMJE’s guidelines for conducting, reporting, and publishing medical research: icmje.org/recommendations/
#cancer #research #science #OA #ebm
Oncotarget retweeted
📈 #TrendingWithImpact:
"Stevens–Johnson syndrome following combination therapy with pembrolizumab and enfortumab vedotin in a patient with metastatic urothelial carcinoma: A rare but serious adverse event"
#PressRelease ⬇️
bit.ly/3Ugxb7J
#UrothelialCancer #Oncoscience
🔎 Over 26,000 Oncotarget papers are now searchable on #PubMed:
pubmed.ncbi.nlm.nih.gov/?ter…
#publishing #cancer #research #openaccess #peerreviewed #journalpublication
Oncotarget retweeted
#PaperoftheDay: "Planetary health and oncology: policy roadmap to mitigate environmental carcinogens in the global south"
DOI ⬇️
doi.org/10.18632/oncoscience…
#Cancer #Oncology #Research #OpenAccess #Publishing #PeerReviewed #Journal
🖥️ Ready to submit your #research to Oncotarget? Start your online submission here:
oncotarget.msubmit.net/cgi-b…
#peerreviewed #journal #openaccess #openscience #publishing #author #cancer #oncology #publication
✅ Could a developmental gene help drive prostate cancer progression?
New #research identifies PDX1 as a potential regulator of insulin, inflammatory, and EMT pathways in prostate cancer.
#Summary ⬇️
oncotarget.org/2026/06/16/pd…
#prostatecancer #cancer #oncology #oa #publishing
🧬 #BehindtheStudy:
Aiden Deacon @umn_dom discusses his #paper, “Dissecting the functional differences and clinical features of R-spondin family members in metastatic prostate cancer.”
youtube.com/watch?v=OXKhWWU1…
#interview #authorinterview #prostatecancer #cancer #research #oa
🗓️ Explore the latest oncology-focused #research published in Volume 17 (2026):
oncotarget.com/archive/v17/i…
#cancer #oncology #publishing #openaccess #openscience #peerreviewed #meded #journal #volume #issue
Oncotarget retweeted
#PaperoftheDay: "Clinical parallels and key distinctions: A diagnostic case of waldenström macroglobulinemia versus igM multiple myeloma"
DOI ⬇️
doi.org/10.18632/oncoscience…
#Cancer #Oncology #Research #OpenAccess #Publishing #PeerReviewed #Journal
✅ How can molecular profiling guide care for patients with multiple cancers?
An #Oncotarget case report explores precision treatment strategies for a woman with a BRCA1 mutation and five primary cancers.
#Summary:
oncotarget.org/2026/10/20/mo…
#PrecisionOncology #Cancer #Blog #OA
🛡️ To maintain scientific integrity and reduce the risk of costly settlements related to image fraud, we recommend institutions subscribe to image forensics tools, establish dedicated image forensics teams, and encourage researchers to screen their manuscripts before publication.
ALT Oncotarget Scientific Integrity
#PaperoftheDay: "WIN-MTB-2024002 – WIN International Molecular Tumor Board: A 52-year-old female with unmeasurable Stage IIIc colon cancer"
DOI ⬇️
doi.org/10.18632/oncotarget.…
#Cancer #Oncology #OpenAccess #Research #Publishing #PeerReviewed #Journal
